---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007074"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:53:06.117942+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA grants RMAT designation to MeiraGTx's AAV-GAD for Parkinson's disease

## Summary
- RMAT designation based on data from three clinical studies (Phase 1 n=12, Phase 2 n=45, dose-ranging n=14).
- AAV-GAD showed significant benefit on UPDRS Part 3 motor endpoint in double-blind sham-controlled trials.
- Hologen AI analysis indicated disease-modifying brain circuitry changes, first in sham-controlled Parkinson's study.
- RMAT includes Fast Track and Breakthrough Therapy benefits, rolling review, and potential Priority Review for BLA.
- MeiraGTx plans to work closely with FDA to advance this one-time gene therapy for Parkinson's disease.

## SEC filing metadata
- accession: 0001558370-25-007074
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837025007074/0001558370-25-007074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837025007074/mgtx-20250509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007074
- JSON: https://secwatch.observer/filing/0001558370-25-007074.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.